Evidence map›Paper›PMID 38858678›Full record

ArticleBMC anesthesiology2024

Sugammadex use in pediatric patients with stage IV-V chronic kidney disease in a quaternary referral hospital: a case series.

Sindhu N Samba, Youssef Daklallah, Sydney E S Brown, Douglas A Colquhoun, Zubin J Modi, Rebecca Nause-Osthoff

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC anesthesiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sindhu N SambaDepartment of Anesthesiology, Pediatric Division, C.S. Mott Children's Hospital, University of Michigan, 4-911 Mott Hospital / 1540 E. Hospital Dr, SPC 4245, Ann Arbor, MI, 48109, USA.
Youssef DaklallahDepartment of Anesthesiology, Pediatric Division, C.S. Mott Children's Hospital, University of Michigan, 4-911 Mott Hospital / 1540 E. Hospital Dr, SPC 4245, Ann Arbor, MI, 48109, USA.
Sydney E S BrownDepartment of Anesthesiology, Pediatric Division, C.S. Mott Children's Hospital, University of Michigan, 4-911 Mott Hospital / 1540 E. Hospital Dr, SPC 4245, Ann Arbor, MI, 48109, USA.
Douglas A ColquhounDepartment of Anesthesiology, University of Michigan, Ann Arbor, MI, USA.
Zubin J ModiDivision of Pediatric Nephrology, Department of Pediatrics, University of Michigan, Ann Arbor, MI, USA.
Rebecca Nause-OsthoffDepartment of Anesthesiology, Pediatric Division, C.S. Mott Children's Hospital, University of Michigan, 4-911 Mott Hospital / 1540 E. Hospital Dr, SPC 4245, Ann Arbor, MI, 48109, USA. rnauseos@med.umich.edu.

Funding

Data Driven Approaches to Improving Risk Prediction of Pulmonary Complications After Major Inpatient SurgeryK08HL159327 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI COLQUHOUN, DOUGLAS ALASTAIR · 2021 to 2025
$811k
NHLBI NIH HHS K08 HL159327
6 · The paper itself

Abstract

backgroundSugammadex is a pharmacologic agent that provides rapid reversal of neuromuscular blockade via encapsulation of the neuromuscular blocking agent (NMBA). The sugammadex-NMBA complex is primarily cleared through glomerular filtration from the kidney, raising the possibility that alterations in renal function could affect its elimination. In pediatric patients, the benefits of sugammadex have led to widespread utilization; however, there is limited information on its application in pediatric renal impairment. This study examined sugammadex use and postoperative outcomes in pediatric patients with severe chronic renal impairment at our quaternary pediatric referral hospital.

methodsAfter IRB approval, we performed a retrospective analysis in pediatric patients with stage IV and V chronic kidney disease who received sugammadex from January 2017 to March 2022. Postoperative outcomes studied included new or increased respiratory requirement, unplanned intensive care unit (ICU) admission, postoperative pneumonia, anaphylaxis, and death within 48 h postoperatively, unplanned deferral of intraoperative extubation, and repeat administrations of NMBA reversal after leaving the operating room.

resultsThe final cohort included 17 patients ranging from 8 months to 16 years old. One patient required new postoperative noninvasive ventilation on postoperative day 2, which was credited to hypervolemia. Another patient had bronchospasm intraoperatively resolving with medication, which could not definitively be associated sugammadex administration. There were no instances of deferred extubation, unplanned ICU or need for supplemental oxygen after tracheal extubation identified.

conclusionNo adverse effects directly attributable to sugammadex in pediatric patients with severe renal impairment were detected. There may be a role for utilization of sugammadex for neuromuscular reversal in this population.

Indexed as

Neuromuscular BlockadeRenal Insufficiency, ChronicSugammadexAdolescentChildChild, PreschoolFemaleHumansInfantMaleNeuromuscular Nondepolarizing AgentsPostoperative ComplicationsRetrospective StudiesNeuromuscular Nondepolarizing AgentsSugammadexChronic kidney diseaseNeuromuscular blockadeOutcomePediatricRecurarizationRenal impairmentSugammadex

Identifiers

PMID38858678
PMCPMC11163781

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.